阿米托细胞分裂,恶性病变和抗癌剂的耐药性:致敬于Drs. 瓦伦和拉贾拉曼曼
Razmik Mirzayans1, David Murray1
1Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Cancers
|September 14, 2024
概括
多倍体巨型癌细胞 (PGCCs) 可以以基分裂方式分裂,产生具有类似干细胞特性的子细胞,这可能会推动瘤生长和治疗耐药性. 这篇评论更新了关于PGCC和阿米托细胞分裂的发现.
科学领域:
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
- 遗传学 遗传学 是一个
背景情况:
- 细胞分裂,包括细胞分裂,半分裂和细胞分裂,是生命的基础.
- 氨酶的特征是核芽,发生在异常的大细胞中,如多倍体细胞.
- 聚类巨型癌细胞 (PGCCs) 存在于瘤中,与治疗耐药性有关.
研究的目的:
- 提供有关多体细胞中阿米托细胞分裂的发现的最新情况.
- 突出聚类巨型癌细胞 (PGCCs) 在瘤发生和治疗耐药性的作用.
- 为了纪念博士们的基础工作. 克里斯·瓦伦和伦加斯瓦米·拉贾拉曼.
主要方法:
- 沃伦和拉贾拉曼在2000年代初对多倍体细胞分裂的研究的回顾.
- 通过化生成的子细胞的特性分析.
- 检查PGCCs对癌症进展和治疗结果的贡献.
主要成果:
- 多倍体人体细胞可以经历氨基分裂,产生后代.
- 这些子细胞的一个子集表现出快速增殖和干细胞类特征.
- PGCCs对瘤复发和对癌症疗法的耐药性有显著的贡献.
结论:
- 聚类细胞,特别是PGCC中的氨基酸细胞分裂代表了癌症发展和治疗失败的重要机制.
- 对PGCC及其独特的分裂过程的进一步研究对于推进癌症治疗至关重要.
- 瓦伦和拉贾拉曼的工作为了解癌症生物学这些关键方面奠定了基础.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


